Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 10 (1), 111-7

Clinical and Pharmacological Experience With LJP-394

Affiliations
Review

Clinical and Pharmacological Experience With LJP-394

D J Wallace. Expert Opin Investig Drugs.

Abstract

LJP-394 is a synthetic biological with immunomodulatory functions. Composed of four double-stranded oligodeoxynucleotides attached to a central branched platform, the drug acts as an anti-"anti-ds-DNA" B-cell toleragen by rendering specific B-lymphocytes unresponsive to immunogen so they do not produce autoantibodies. Extensive animal studies and Phase II clinical trials suggested that the effects of LJP-394 are effective and safe when used as a weekly dose of 100 mg intravenously. Analysis of a multicentre, international Phase II/III clinical trial showed that patients with lupus nephritis and high affinity IgG antibodies to LJP-394 have clinical benefits. This includes increased time to renal flares, reduced number of renal flares, time to institution of high-dose corticosteroids and/or cyclophosphamide and lower anti-ds-DNA levels. A definitive trial is in progress. LJP-394 appears to be free of serious adverse reactions. Though promising, the role of LJP-394 in patients with active, organ-threatening lupus is still not known.

Similar articles

See all similar articles

Cited by 3 PubMed Central articles

  • Novel Approaches to Therapy for SLE
    G Zandman-Goddard et al. Clin Rev Allergy Immunol 25 (1), 105-12. PMID 12794265. - Review
    Systemic lupus erythematosus (SLE) is an autoimmune disease manifested by multi-organ involvement and elevated titers of anti-DNA antibodies. Current therapies for SLE ar …
  • Newer Drugs for the Treatment of Lupus Nephritis
    DG Kuiper-Geertsma et al. Drugs 63 (2), 167-80. PMID 12515564. - Review
    This article first reviews the current treatment of lupus nephritis, with a focus on the most serious forms, that is, the proliferative subtypes. Current standards for tr …
  • Treatment Options for Juvenile-Onset Systemic Lupus Erythematosus
    L Carreño et al. Paediatr Drugs 4 (4), 241-56. PMID 11960513. - Review
    Systemic lupus erythematosus (SLE) is an inflammatory chronic disease characterized by the presence of activated helper T-cells that induce a B-cell response, resulting i …

MeSH terms

LinkOut - more resources

Feedback